Your shopping cart is currently empty

PROTACBRD4 Degrader-39 is a selective degrader targeting BRD4, with a DC50 value of 24.66 nM. It combines BRDPROTAC(ARV-771) with a carbohydrate, allowing selective delivery to tumor cells with high GLUT1 expression. Upon glutathione activation, ARV-771 is released, leading to BRD4 degradation. This compound can suppress tumor growth without significant toxicity and is useful for cancer research, including studies on breast cancer.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | PROTACBRD4 Degrader-39 is a selective degrader targeting BRD4, with a DC50 value of 24.66 nM. It combines BRDPROTAC(ARV-771) with a carbohydrate, allowing selective delivery to tumor cells with high GLUT1 expression. Upon glutathione activation, ARV-771 is released, leading to BRD4 degradation. This compound can suppress tumor growth without significant toxicity and is useful for cancer research, including studies on breast cancer. |
| Targets&IC50 | BRD4:24.66 nM (DC50) |
| In vitro | PROTAC BRD4 Degrader-39 (Compound NG-2) effectively degrades BRD4 in a concentration- and time-dependent manner (0.01-10 μM, 3-48 h) in MDA-MB-231 cells. It relies on glucose transporters and the proteasome for BRD4 degradation. Additionally, PROTAC BRD4 Degrader-39 (5-5000 nM, 3 h) shows efficacy in degrading BRD4 in MDA-MB-157, MCF-7, T-47D, and BEAS-2B cells. Moreover, it is not readily recognized by P-glycoprotein, allowing it to effectively evade efflux in Caco-2 cells. |
| In vivo | The compound PROTAC BRD4 Degrader-39 (Compound NG-2), administered at a dosage of 2.5 mg/kg via intraperitoneal injection every other day for a total of 14 doses, effectively inhibits tumor growth in the MDA-MB-231 mouse model. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.